Immune checkpoint inhibitors have significantly improved outcomes in relapsed or refractory Hodgkin lymphoma (rrHL). Pembrolizumab, a programmed death-1 inhibitor, is generally well tolerated but may induce immune-related adverse events (irAE), including rare sarcoid-like reactions that can mimic disease progression. We report the case of a 30-year-old woman with refractory classical Hodgkin lymphoma (cHL) who developed pulmonary sarcoid-like granulomatous inflammation during pembrolizumab therapy.
Zinzani, P.L., Salvatore, F., Casadei, B., Mazzoni, C., Gentilini, M., Gabrielli, G., et al. (2026). Sarcoid-like Reactions in Hodgkin Lymphoma Treated with Pembrolizumab: a Case Report. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 18(1), 1-3 [10.4084/mjhid.2026.052].
Sarcoid-like Reactions in Hodgkin Lymphoma Treated with Pembrolizumab: a Case Report
Zinzani, Pier Luigi
;Salvatore, Flavia;Casadei, Beatrice;Mazzoni, Camilla;Gentilini, Marianna;Gabrielli, Giulia;Argnani, Lisa
2026
Abstract
Immune checkpoint inhibitors have significantly improved outcomes in relapsed or refractory Hodgkin lymphoma (rrHL). Pembrolizumab, a programmed death-1 inhibitor, is generally well tolerated but may induce immune-related adverse events (irAE), including rare sarcoid-like reactions that can mimic disease progression. We report the case of a 30-year-old woman with refractory classical Hodgkin lymphoma (cHL) who developed pulmonary sarcoid-like granulomatous inflammation during pembrolizumab therapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
Zinzani+PDF.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale / Version Of Record
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
403.1 kB
Formato
Adobe PDF
|
403.1 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
